Adult Immunization

Your daily dose of the clinical news you may have missed.

New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.

A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

More than 90% of adults making nonurgent ED visits had missed at least 1 CDC-recommended vaccine but many were willing to catch up on all of them while there.

Z-1018, which combines a glycoprotein E (gE) antigen and proprietary adjuvant, was evaluated in adults aged 50 to 69 and the 100 µg dose will advance to part 2 of the trial.

New data show more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during National Immunization Awareness Month.

A recent poll reveals most US adults are hesitant about fall COVID-19 vaccinations, highlighting confusion over federal policies and declining trust in health agencies.

Danish adults aged 65 and older at high-risk for serious infection with SARS-CoV-2 showed no increased risk of 29 serious adverse events following vaccination.

Schaffner describes the mood among his colleagues in infectious disease right now as anxious, perplexed, distressed, and angry. They expect the disruptions and their feelings to continue.

Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.

Amesh Adalja, MD, explains how physicians can rebut social media vaccine claims with concise, referenced facts and patient-centered communication.

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

The prefilled syringe presentation streamlines administration of the vaccine, eliminating the need to combine the lyophylized antigen and separate adjuvant.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.

Your daily dose of the clinical news you may have missed.

Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.